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Abstract The mitogen-activated protein kinase, ERK is acti-
vated by a dual phosphorylation on threonine and tyrosine 
residues. Using a synthetic diphospho peptide, we have generated 
a monoclonal antibody directed to the active ERK. The antibody 
specifically identified the active doubly phosphorylated, but not 
the inactive mono- or non- phosphorylated forms of ERKs. A 
direct correlation was observed between ERK activity and the 
intensity in Western blot of mitogen-activated protein kinases 
from several species. The antibody was proven suitable for 
immunofluorescence staining, revealing a transient reactivity 
with ERKs that were translocated to the nucleus upon 
stimulation. In conclusion, the antibody can serve as a useful 
tool in the study of ERK signaling in a wide variety of organisms. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Mitogen-activated protein kinases (MAPKs) are a family of 
highly homologous serine/threonine protein kinases that play 
a key role in the transmission of many extracellular signals 
(reviewed in [1-3]). The MAPKs share a common mechanism 
of activation which involves the phosphorylation of both 
threonine and tyrosine residues in a Thr-Xaa-Tyr (TXY) mo-
tif [4] positioned in their activation loop. Based on the identity 
of the residue in between the threonine and the tyrosine, the 
MAPK family can be divided into three main groups: the 
TEY group that includes the well-characterized ERK1 and 
ERK2 (p42 and p44 MAPKs; [5,6]) and also the big 
MAPK (ERK5; [7]); the TPY group that includes the 
JNK1 and JNK2 (SAPKs; [8,9]); and the TGY group that 
includes the p38 MAPK (HOG, RK, CSBP; [10-12]) and 
ERK6 [13]. Although the MAPKs are activated in response 
to a wide variety of extracellular stimuli, the extent of activa-
tion seems to vary between different stimuli. It is generally 
accepted that signals which induce proliferation and differen-
tiation activate primarily the ERK1 and ERK2 of the TEY 
group, whereas agents which cause a cellular stress response 
mainly activate the TGY and TPY MAPKs [14]. 
The activation of the MAPKs is mediated by specific pro-
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of ERK and contains the regulatory threonine and tyrosine 
tein kinases that arc collectively known as MAPK kinases 
(MAPKKs [1,15]). These MAPKKs are capable of phospho-
rylating both threonine and tyrosine residues in the TXY mo-
tif to cause a full activation of their downstream MAPK [15]. 
In spite of the extensive homology among the various isoforms 
of MAPK or MAPKK, in most cases the MAPKKs are spe-
cific to their downstream targets, and thereby form parallel 
linear pathways, both in lower organisms [16] and in mammals 
[1]. However, some 'cross-talk' between the MAPK cascades 
may exist in the case of the TPY and TGY kinases [17]. 
While the processes that lead to ERK activation are re-
solved, the inactivation mechanism of MAPKs is less well 
understood and appears to involve a battery of phosphatases. 
It should be noted that removal of phosphate from one of the 
phosphorylated threonine or tyrosine residues is sufficient to 
completely abolish MAPK activity [15]. Indeed, in the case of 
ERK1 and ERK2 the immediate inactivation process seems to 
involve protein serine/threonine phosphatases [18] whereas the 
inactivation that occurs in a somewhat delayed time course 
seems to be mediated by a dual specificity phosphatase specific 
for MAPK [19]. Thus, few minutes after treatment of cells 
with growth factors, doubly phosphorylated ERKs are found 
to co-exist along with the inactive, mono-phosphorylated and 
unphosphorylated forms of the ERKs. 
In this paper, we describe a monoclonal anti-active ERK 
antibody that was generated by immunizing mice with a syn-
thetic peptide containing 11 amino acids of the ERK activa-
tion loop, in which the threonine and tyrosine residues were 
phosphorylated. This antibody displays a remarkable specific-
ity towards active ERKs and is shown to be efficient in im-
munofluorescence studies. In view of the structural conserva-
tion of ERK, this antibody can serve as a very useful tool in 
the study of signaling processes in a wide variety of species. 
2. Materials and methods 
2.1. Antibody development 
The monoclonal anti-activated MAPK (diphosphorylated ERK1 
and ERK2) (clone MAPK-YT) was raised against a diphospho pep-
tide containing the 11 amino acid HTGFL(p)TE(p)YVAT corre-
sponding to the phosphorylated form of the ERK activation loop. 
For immunization, the peptide was conjugated to KLH using the 
Maleimide Activated BSA/KLH Conjugation Kit (Sigma, MBK-I). 
BALB/c mice were immunized and their spleen cells were fused with 
NS-1 mouse myeloma cells. Hybridoma supernatants were screened 
for specific antibodies by ELISA on a BSA conjugate of the above 
peptide, and by Western blotting of cell extracts. One clone termed 
MAPK-YT, which secretes lgGI antibodies (Sigma Immunotype TM 
Kit ISO-1), was selected. The antibody is now commercially available 
(Sigma Chemical Company). 
2.2. ELISA assay 
Antibody specificity was determined by ELISA. For this purpose, 
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Fig. 1. Competition of MAPK-YT monoclonal antibody binding. 
Antibody binding to the BSA conjugated, doubly phosphorylated 
ERK peptide was competed by the pTEpY ( · ) . pTEY (O), TEpY 
(G) and the non-phosphorylated TEY ( Δ ) peptides of ERK and 
with doubly phosphorylated peptides derived from the activation 
loops of JNK1 (■) and p38 MAPK ( A ) . The antibody binding was 
detected by ELISA as described in Section 2. 
wells were coated overnight with 2 μ§/piι1 of peptide-BSA conjugates. 
The assessment of MAPK-YT antibody specificity was performed by 
a competitive ELISA assay where antibody binding to the peptide 
conjugate was inhibited with 1 ng/ml-100 μg/ml of free non-phos-
phorylated form of the above peptide (TEY), diphosphorylated pep-
tide (pTEpY), or each of the mono-phosphorylated peptides (pTEY. 
TEpY) of the ERK protein sequence. Doubly phosphorylated pep-
tides of the activation loop from JNK (pTPpY) or p38 MAPK 
(pTGpY) were also used for competition. Bound antibody was de-
tected with Peroxidasc conjugated goat anti-mouse IgG antibody 
(Sigma). 
2.3. Western blotting 
To monitor the accumulation of doubly phosphorylated ERK, we 
analyzed cell extracts from stimulated and unstimulated cells. Cells 
were grown stimulated and lysed as previously described [20]. The 
cell extracts were separated on a 12% SDS-PAGE gel, and blotted 
onto nitrocellulose. Activated ERK was detected by probing blots 
with a 1:30000 dilution of the monoclonal antibody (MAPK-YT). 
Total ERK protein (activated and non-activated) was detected using 
a 1:40000 dilution of a polyclonal rabbit antibody directed towards 
subdomain XI of the ERKs (Sigma; termed here general anti-MAPK). 
The blots were developed by Alkaline Phosphatase conjugated anti-
mouse or anti-rabbit Fab (Sigma), or by horseradish peroxidase con-
jugated anti-mouse or anti-rabbit Fab and F.CL (Amersham). 
2.4. ¡mmunoprecipitation of ERK mutants 
COS7 cells were grown in DMEM+10% fetal calf serum (FCS) in 
10 cm plates were transfected (DEAE-dextran; [20]) with 10 μg of 
hemagglutinin (HA) tagged wild type ERK2, or the phosphorylation 
site mutants of ERK2, HA-T183E-ERK2 (EEY), HA-Y185F-ERK2 
(TEF) or HA-T183E,Y185F-ERK2 (EEF) that were cloned in the 
mammalian expression vector pCDNAl (Invitrogen). One day later, 
each plate was divided into two, and these were serum starved (0.1% 
FCS, 16 h) for additional 24 h. One plate of each pair was stimulated 
with 100 μΜ Na3V04 and 200 μΜ Η 2 0 2 for 18 min, and the other 
plate served as a basal control. After stimulation, the cells were 
washed, lysed and the ERKs were immunoprecipitated with a mono-
clonal anti-HA (Antibodies Unit, WIS) using protein A-agarose (20 
μΐ, Sigma) as described [20]. The immunoprecipitates were subjected 
to SDS-PAGE and Western blotting as above. 
2.5. Determination of ERK activity 
Serum starved (0.1% FCS, 16 h) NIH-3T3, Ratl and HeLa cells 
were stimulated with EGF (50 ng/ml) for the desired time. After 
stimulation, the cells were washed, lysed and ERKs were immunopre-
cipitated with anti-ERK antibody (C14, Santa-Cruz Biotechnology, 
Inc., CA) using protein A-agarose (20 μΐ, Sigma). ERK activity was 
determined by the phosphorylation of myelin basic protein (MBP) as 
previously described [20]. 
2.6. Fluorescent cell staining 
Serum starved (0.1% FCS, 16 h) N1H-3T3, Ratl and HeLa cells 
were treated either with EGF (50 ng/ml) for 10 and 30 min or with 
Fig. 2. MAPK-YT monoclonal antibody is specific to the active, doubly phosphorylated form of ERK2. A: COS7 cells were transfected with 
HA tagged wild type ERK2 (TEY), HA-T183E-ERK2 (EEY), HA-Y185F-ERK2 (TEF) or HA-TI83E,Y185F-FRK2 (EEF). Each plate was 
divided into two and these were serum starved followed by stimulation of one of them with peroxovanadate (20 min) as described. After stimu-
lation, the cells were lysed and the ERKs were immunoprecipitated with monoclonal anti-HA antibodies and subjected to SDS-PAGE and 
western blotting. B: The wild type ERK that was immunoprecipitated from the peroxovanadate activated cells was subjected to SDS-PAGE 
and blotted onto nitrocellulose. Separate lanes of this blot were incubated with the MAPK-YT monoclonal antibody in the presence of the 
pTEpY, TEpY, pTEY, TEY or no peptide (50 μg/ml each). 
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10% FCS for 30 min. Subsequently, the cells were washed with phos-
phate buffered saline (PBS) and fixed in 3% formaldehyde in PBS 
solution for 20 min. Following additional washes with PBS, the cells 
were permeabilized with 0.1% Triton X-100 in PBS for 5 min. Co-
staining was performed by 45 min incubation with the monoclonal 
antibody MAPK-YT (1:50) together with the general polyclonal Rab-
bit anti-MAPK antibody (Sigma), followed by 45 min incubation with 
a mixture of rhodamine conjugated goat anti-mouse IgG and FITC 
conjugated goat anti-rabbit IgG antibodies (both 1:200, Jackson Im-
munoresearch Laboratories). Fluorescent staining was viewed with a 
1024 confocal microscope (Bio-Rad Laboratories). 
3. Results and discussion 
A monoclonal antibody, termed anti-activated MAPK (di-
phosphorylated ERK1 and ERK2; clone MAPK-YT), was 
raised against an eleven amino acid peptide, derived from 
the activation loop of vertebrate ERKs which contained phos-
phorylated threonine and tyrosine residues. In ELISA, the 
antibody recognized strongly the doubly phosphorylated im-
munizing peptide and negligibly the non-phosphorylated TEY 
peptides (data not shown). In order to further study the spe-
cificity of the antibody, we examined the ability of the mono-
phosphorylated and non-phosphorylated peptides to compete 
out the binding of the antibodies to the immunizing peptide 
antigen in a competitive ELISA assay. The only peptide that 
efficiently competed with antibody binding was the doubly 
phosphorylated peptide pTEpY (IC50< 10 ng/ml; Fig. 1), 
whereas the other peptides competed in much higher concen-
trations (IC50 > 100 \L^m\ for TEpY, pTEY and TPY; Fig. 1). 
By the same assay we could also show that the binding of the 
monoclonal antibody (MAPK-YT) was not competed by dou-
bly phosphorylated peptides derived from the TPY and TGY 
motif enzymes JNK1 and p38MAPK respectively (Fig. 1). 
Since in ELISA the monoclonal antibody (MAPK-YT) ap-
peared to selectively recognize the doubly phosphorylated 
peptide, we undertook to test whether this will also be true 
for the whole protein. Thus, COS7 cells were transfected with 
hemagglutinin (HA) tagged constructs of ERK2, or its phos-
phorylation site mutants. These cells were activated by perox-
ovanadate which is a strong general stimulator of several 
MAPKs [21], and ERK protein was immunoprecipitated 
with anti-HA antibodies. Western blot analysis of the immu-
noprecipitated proteins revealed that although there was a 
similar amount of ERK2 in each of the immunoprecipitates, 
the anti-active MAPK monoclonal antibody (MAPK-YT) rec-
ognized primarily the wild type ERK2 (TEY) and to some 
extent (3.5% of the wild type) also the T183E (EEY), but 
not the Y185F (TEF) or the T183E,Y185F (EEF) mutants 
(Fig. 2A). The recognition of ERK was efficiently competed 
with the doubly phosphorylated pTEpY peptide but not by 
the other phosphorylation site peptides (pTEY, TEpY, and 
TEY; Fig. 2B). These results further demonstrate the specif-
icity of the monoclonal antibody (MAPK-YT) to the doubly 
phosphorylated, active form of ERK. The fact that the T183E 
mutant, that contains only the phosphorylated tyrosine, was 
recognized to some extent by the antibody is most likely due 
to the acidic moiety of the glutamic acid that mimics that of 
the phosphate in that position. Thus, the actual difference in 
extent of recognition between the mono-tyrosine phosphoryl-
ated and doubly phosphorylated ERKs is probably much 
higher than that observed in the Western blot assay, and 
should be closer to the difference demonstrated in the ELISA 
competition assays. 
Fig. 3. Comparison of ERK activity and staining by the MAPK-YT 
monoclonal antibody in EGF stimulated NIH-3T3, Ratl and HeLa 
cells. NIH-3T3, Ratl and HeLa cells were stimulated with EGF (50 
ng/ml) for the indicated times, harvested and lysed as described. Ly-
sats were then subjected to a western blot analysis with the MAPK-
YT monoclonal or with the general anti MAPK polyclonal antibod-
ies (developed by the alkaline phosphatase method), and ERK activ-
ity was assayed by phosphorylation of MBP after immunoprecipila-
tion with anti C-terminus antibodies as described. The amount of 
immunoreactivity in the blots ( · ) or in the autoradiograms of the 
kinase assays (o) was determined (Bio-Rad 690 densitometer) and 
plotted as % of maximal activity of the separate experiments. 
In order to further characterize the antibody, we wanted to 
determine whether the intensity of detection by this antibody 
in Western blot fully correlates with ERK activity. Therefore, 
NIH-3T3, Ratl and HeLa cells were stimulated with EGF 
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Fig. 4. Western blot analysis of cell extracts from various organisms with the MAPK-YT monoclonal antibody. Cells (106 cells per reaction) 
from alga (Dunaíiella salina), yeast (w303), insects (Spodoplera frugiperda Sf9 and Drosophila Schneider S2 cells) and mammals (NIH-3T3 
(mouse), Ratl (rat), HeLa (human), and HepG2 (human)) were either treated with the general activator VOOH (100 μΜ vanadate and 200 
μΜ Η202; 20 min, 37°C) or left untreated. The cells were harvested, and the cell extracts were separated by SDS-PAGE as in Section 2. Active 
MAPK was detected using 1:30000 dilution of the MAPK-YT monoclonal antibody and the blots were developed either by the alkaline phos-
phatase (alga and yeast) or by the ECL methods. 
and their cytosolic extracts were examined for ERK activity 
towards MBP after immunoprecipitation with anti-ERK C-
terminus antibody, as well as for the intensity of staining by 
the MAPK-YT monoclonal antibody in Western blot analy-
sis. A direct correlation between ERK activity and the recog-
nition by the antibody was observed in all cell types (Fig. 3), 
verifying that the antibody is a valid tool to determine MAPK 
activation in vivo. Interestingly, the time course of ERK acti-
vation by EGF varied between the three cell types. In the 
NIH-3T3 cells, the activation was transient, peaked at 5 min 
after the addition of EGF and decreased thereafter. On the 
other hand, the activation of ERKs in HeLa and Ratl cells 
was more prolonged; in both cells it peaked at 10 min after 
stimulation and remained high for the next 50 min, demon-
strating a pattern of sustained activation. It was previously 
shown that the duration of ERK signal may determine cell 
fate in some cell types such as PC 12 cells, where transient 
activation leads to proliferation, and sustained ERK activa-
tion leads to differentiation (reviewed in [3]), However, in the 
cells examined here, Ratl and HeLa, the mitogenic agent 
EGF, caused sustained activation which did not seem to block 
proliferation. The role of the sustained activation in these cells 
Fig. 5. Staining of unstimulated and stimulated NIH-3T3, Ratl and HeLa cells with MAPK-YT monoclonal antibody and general anti-
MAPK. NIH-3T3, Ratl and HeLa cells were grown on microslides for 48 h, serum starved (16 h) and stimulated by EGF (50 ng/ml 10 and 30 
min) or by serum (10%, 30 min). The cells were fixed, permeabilized and stained as described in Section 2. The cells were viewed by confocal 
microscope (objective X40, zoom 4). Both green (general anti-MAPK) and red (anti-active MAPK) channels of the same cells are presented 
(left and right sides of each panel respectively). Since each slide was stained separately, the differences in intensity between the different treat-
ments may not be accurate. 
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is not known but may indicate that in these cells ERKs have 
additional roles in later processes. 
It should be also noted that small differences between the 
rate of ERKl and ERK2 activation was detected in some of 
the cell lines. Thus, in NIH-3T3 cells, the activation of ERKl 
appeared to precede that of ERK2 (2.5 min) whereas the 
activation of ERK2 remained high slightly longer (Fig. 3, 
upper panel). In HcLa cells ERK2 was predominantly acti-
vated and only some ERKl specific activation was detected 
10-^ 15 min after stimulation (Fig. 3, middle panel). On the 
other hand, in Ratl cells the activation of both isoforms oc-
curred simultaneously, but a gradual appearance of a 46 kDa 
band was detected that occurred in a slower time course than 
ERKl and ERK2 (Fig. 3, bottom panel). This band may 
correspond to the poorly characterized ERK4 that was previ-
ously identified through the use of anti-MAPK antibodies [22]. 
Since the TEY activation motif of MAPKs is conserved 
throughout evolution, we examined the ability of the antibody 
to specifically recognize the active form of MAPK of various 
organisms. Indeed, enhanced intensity of bands around 40 
kDa was observed upon peroxovanadate activation of yeast, 
insects, and mammalian cells (but not the alga Dulaniela; Fig. 
4). In yeast, three proteins were detected by the antibody, two 
of them at 40 and 48 kDa, are probably MAPKs [16], whereas 
the nature of the lower molecular weight band is not known. 
As expected [23], in insect cells only one form of MAPK was 
recognized by the antibody, whereas in mammalian cells, sev-
eral bands were detected, that were also recognized by general 
anti-MAPK antibody (not shown). Thus, in NIH-3T3 cells the 
MAPK-YT monoclonal antibody detected the well known 42 
and 44 kDa MAPKs (ERK2 and ERKl) that were also de-
tected in Ratl cells, in addition to a 46 kDa band that was 
detected after longer exposure. However, in the human cells 
HeLa and HepG2, the position of the bands was at 42 and 43 
kDa. This difference in migration could be either due to 
changes in primary sequence of ERKl that were not previ-
ously reported, or due to different post-translational modifi-
cations other than the phosphorylation of the TEY motif. 
Another property of the MAPK-YT monoclonal antibody 
was its ability to stain active ERK by immunocytochemical 
techniques. Thus, stimulated NIH-3T3, Ratl and HeLa cells 
were stained with both the MAPK-YT monoclonal antibody 
and the general polyclonal anti-MAPK antibody (Fig. 5). As 
expected [24], the staining of non-stimulated cells with the 
general anti-MAPK antibody was detected primarily in the 
cytosol, which turned nuclear (at least in part) upon stimula-
tion. However, the staining with the anti-active MAPK mono-
clonal antibody (MAPK-YT) did not follow that of the gen-
eral ERKs. In the basal state, some weak staining was 
detected in the cytosol of the three cell lines, which enhanced 
in intensity upon activation. In spite of the massive translo-
cation of ERKs to the nucleus, appreciable nuclear staining 
was observed in NIH-3T3 and HeLa cells only 10 min after 
EOF stimulation but not 30 min after EGF or serum treat-
ment of the same cells, and not at all in Ratl cells. These 
results, which were corroborated by cellular fractionation 
and activity assays (Rubinfeld and Seger, unpublished), may 
indicate that in these cells, active ERK is translocated to the 
nucleus shortly after stimulation and this is followed by a 
rapid inactivation of ERK. Therefore, the sustained activation 
obtained in HeLa and Ratl cells (Fig. 3) is probably due to 
slower inactivation in the cytosol and can not be attributed to 
the nuclear MAPK phosphatases observed in other cell lines 
[19,25]. The mechanism of this down-regulation and its exact 
localization are not clear as yet. 
In summary, we report here on the development of a novel, 
monoclonal antibody which specifically identifies the active 
(doubly phosphorylated) but not the inactive (mono- or 
non-phosphorylated) forms of ERKs. This antibody has 
been used here to show transient activation of ERK in the 
nucleus, and in a separate study [26] to study MAPK activa-
tion during Drosophila development. Therefore, the MAPK-
YT monoclonal antibody can serve as a convenient and useful 
tool to study MAPK activation in many organisms. 
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